Related Experiment Video
Updated: Jun 5, 2026

Murine Endoscopy for In Vivo Multimodal Imaging of Carcinogenesis and Assessment of Intestinal Wound Healing and Inflammation
Published on: August 26, 2014
Crohn's disease: CT enterography manifestations before and after treatment
Ying-Wei Wu1, Yong-Hua Tang, Nan-Xin Hao
1Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, 197 Ruijin Er Rd, Shanghai, China. wuyw0103@hotmail.com
Purpose:
The purpose of this study was to determine whether CT enterography (CTE) changes of Crohn's disease (CD) after treatment correlated with clinical remission.
Materials And Methods:
We retrospectively studied 50 known CD patients (male: 35; female: 15) with clinical remission in a period of 3 years (2005-2008). CD was diagnosed by clinical, enteroscopic and pathologic manifestations. Clinical remission was identified by experienced gastroenterologists using the combing criteria of clinical, endoscopy and laboratory tests. First CTE and endoscopy exams were performed during their first hospitalization in our hospital meanwhile CD diagnosis was made during that time. Repeated CTE and endoscopy exams were done after treatment. CTE findings were determined by two experienced radiologists with double-blind approach. Each patient was analyzed for the CTE parameters including bowel wall attenuation, bowel wall thickening (>3mm), bowel wall thickening types (type A: multilayered mural stratification; type B: two layers with strong mucosal enhancement and prominent low-density submucosa; type C: two layers without strong mucosal enhancement; type D: homogeneous enhancement) comb sign, luminal stenosis (mild: luminal diameter 2-3 cm; moderate: luminal diameter 1-2 cm; severe: luminal diameter<1cm) and the presence of extraenteric complications (such as fistulas and abscess). All the quantitative parameters were measured three times by each review.
Results:
After treatment, bowel wall thickening was attenuated in 88% of CD patients. Thickness of bowel wall was decreased from 8.8 ± 2.8mm to 6.4 ± 1.9 mm (P<0.001). CT value of bowel wall in portal stage was also declined from 90.0 ± 15.4 (HU) to 73.4 ± 14.2 (HU (P<0.001). The percentage of patients with type A or B bowel wall thickening was decreased from 78.7% to 35.4%, while those with type C or D thickening was increased from 21.2% to 64.6% (P<0.001). The percentage of patients with comb sign was decreased from 88% to 60% (P=0.001). The percentage of patients with moderate or severe luminal stenosis was reduced from 74% to 32% (P<0.001). The ROC (receiver operating characteristic) analysis showed bowel wall attenuation (A(z)=0.89) and bowel wall thickness (A(z)=0.81) were the two best parameters to predict disease activity, and combining of these two values was better than using them solely (κ=0.71, P<0.001). The bowel wall attenuation (OR=9.56, P<0.001) and bowel wall thickness (OR=3.32, P=0.001) were significantly correlated with the disease activity in the following logistic regression analysis.
Conclusion:
Therapeutic effect of CD and disease activity can be properly evaluated by CTE.
Related Concept Videos
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory Bowel Disease IV: Clinical Manifestations
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease I: Introduction
Inflammatory Bowel Disease III: Crohn's Disease
